Filters
Patients with immune-mediated inflammatory disease (IMID) are at increased risk of hospitalization for heart failure (HF) when compared to the general population, reveals a study.
Survivors of childhood cancer undergo accelerated ageing, with a recent study showing a 2-decade earlier onset and a greater lifetime risk of common and life-threatening chronic health conditions (CHCs).
The consumption of ultraprocessed foods (UPFs) is high among preschool-age children, which can lead to an increase in their diastolic blood pressure (DBP), a study in Canada has shown.
For patients with venous thromboembolism (VTE) who are initiating an oral anticoagulant, apixaban use appears to be safer than rivaroxaban and warfarin, with lower risks of VTE recurrence and major bleeding, as reported in a study.
Children born with mild low birthweight (LBW) are at increased risk of hypertension, according to new research.
In the FLASH study, a recently developed artificial intelligence-based quantitative coronary angiography (AI-QCA) system is noninferior to optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI) in achieving optimal post-PCI minimal stent area (MSA) in patients with less complex coronary artery disease (CAD).
An individual’s gut microbiota profile appears to be associated with chronic heart failure (CHF) risk factors, potentially mediated by microbial metabolites, results of a recent study have shown.
A novel pocket compression device has shown similar efficacy to conventional methods in preventing the occurrence of pocket hematoma, making it a potential alternative for reducing complications following cardiac implantable electronic device (CIED) implantation without additional adverse effects.
Nonrheumatic streptococcal pharyngitis-associated myocarditis (SPAM) appears to occur more frequently than previously believed, particularly in young men presenting with sore throat and fever, suggests a recent study.
Inhibition of angiopoietin-like 3 (ANGPTL-3) with SHR-1918 leads to further low-density lipoprotein cholesterol (LDL-C) reductions in patients at increased risk of atherosclerotic cardiovascular disease (ASCVD), a phase II study has shown.
